OBRIXTAMIG
UNII Y09G7LIC1A

Substance Identification & Data

This profile provides standardized clinical and technical data for Obrixtamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Y09G7LIC1A.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2851943-09-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Y09G7LIC1A

CAS Registry Number

2851943-09-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

OBRIXTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C177765

National Cancer Institute reference terminology for clinical and research data.

INN ID

12889

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Obrixtamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Obrixtamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Obrixtamig

Common Names & Synonyms

Immunoglobulin, bispecific, anti-(human CD3 antigen) (human-Mus musculus monoclonal BI 764532 λ-chain) fusion protein with peptide linker (38-amino acid) fusion protein with immunoglobulin G1 [242-alanine,243-alanine,374-serine,376-alanine,415-valine,443-arginine,444-phenylalanine,de-C-terminal-lysine] anti-(human CD3 antigen) (human-Mus musculus monoclonal BI 764532 γ1-chain), (487→485′),(490→488′)-bis(disulfide) with immunoglobulin anti-(human Notch ligand DLL3) (human-Mus musculus monoclonal BI 764532 κ-chain) fusion protein with peptide linker (38-amino acid) fusion protein with immunoglobulin G1 [241′-alanine,242′-alanine,373′-tryptophan,de-C-terminal-lysine] anti-(human Notch ligand DLL3) (human-Mus musculus monoclonal BI 764532 γ1-chain)

L-kappa-H-gamma1 (knob) chain anti-DLL3 (1-705) [L-kappa anti-DLL3 (1-214) [V-KAPPA (Homo sapiens IGKV1-17*03 (94.9%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-mer (GGGGSE GKSSGSGSES KSTEGKSSGS GSESKSTGGGGS) linker (215-252) -H-gamma-1 heavy chain anti-DLL3 (253-705) [VH (Homo sapiens IGHV1-46*01 (92.9%) -(IGHD) -IGHJ6*01 (94.7%), CDR-IMGT [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo sapiens IGHG1*03, G1m3, nG1m1, CH1 R120, CH3 E12, M14, G1v14 CH2 A1.3, A1.2, G1v32 CH3 W22 (knob) (CH1 R120 (473) (377-474), hinge 1-15 (475-489), CH2 L1.3>A (493), L1.2>A (494) (490-599), CH3 E12 (615), M14 (617), T22>W (625) (600-704), CHS K2>del (705)) (377-705)]]; L-lambda6-H-gamma1 (hole) chain anti-CD3E (1-707) [L-lambda6 anti-CD3 (1'-215') [V-LAMBDA Musmus/Homsap (Mus musculus IGLV1*01 (82.3%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (76.8%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo sapiens IGLC6*01 (100%) (110'-215')] -38-mer (GGGGSE GKSSGSGSES KSTEGKSSGSGSESKSTGGGGS) linker (216'-253') -H-gamma-1 anti-CD3E (254'-707') [VH Musmus/Homsap (Mus musculus IGHV10-1*02 (92.9%) -(IGHD) -IGHJ3*01 (100%)/Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ6*01 (81.8%) T123>L (373'), S128>A (378'), CDR-IMGT [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo sapiens IGHG1*03, G1m3, nG1m1, CH1 R120, CH3 E12, M14, G1v14 CH2 A1.3, A1.2, G1v33 CH3 S22, A24, V86 (hole), G1v83 CH3 R115, F116 (CH1 R120 (475') (379'-476'), hinge 1-15 (477'-491'), CH2 L1.3>A (495'), L1.2>A (496') (492'-601'), CH3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), CHS K2>del (707')) (379'-707')]]; dimer (485-487':488-490')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

immunoglobulin L-kappa-H-gamma1_L-lambda-H-gamma1, anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], bispecific

obrixtamig [INN]